US4401820A
(en)
*
|
1981-01-23 |
1983-08-30 |
Tanabe Seiyaku Co., Ltd. |
Process for racemizing optically active α-amino acids or a salt thereof
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
EP0365685B1
(en)
|
1988-03-30 |
1995-01-18 |
Toray Industries, Inc. |
Freeze-dried composition comprising a horseradish peroxidase-labelled Fab' fragment of an anti-human interferon-beta monclonal antibody and trehalose; EIA kit containing the composition
|
DE68908175T2
(de)
|
1988-05-27 |
1994-03-03 |
Centocor Inc |
Gefriergetrocknete formulierung für antikörperprodukte.
|
WO1994006448A1
(en)
|
1992-09-16 |
1994-03-31 |
The Scripps Research Institute |
Human neutralizing monoclonal antibodies to respiratory syncytial virus
|
JPH11510170A
(ja)
|
1995-07-27 |
1999-09-07 |
ジェネンテック インコーポレーテッド |
タンパク質の処方
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
ZA966075B
(en)
|
1995-07-27 |
1998-01-19 |
Genentech Inc |
Protein formulation.
|
DE69609188T2
(de)
|
1995-09-18 |
2000-12-21 |
Intracel Corp |
Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
|
US20070059302A1
(en)
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
MXPA01005515A
(es)
|
1998-12-01 |
2003-07-14 |
Protein Design Labs Inc |
Anticuerpos humanizados para gamma-interferon.
|
CN100553678C
(zh)
|
1999-02-22 |
2009-10-28 |
巴克斯特国际有限公司 |
新的无白蛋白的因子ⅷ制剂
|
AU3873200A
(en)
|
1999-03-11 |
2000-09-28 |
Schering Corporation |
Mammalian cytokines; related reagents and methods
|
US7090847B1
(en)
|
1999-09-09 |
2006-08-15 |
Schering Corporation |
Mammalian cytokines; related reagents and methods
|
MXPA02002684A
(es)
|
1999-09-09 |
2002-07-30 |
Schering Corp |
Citocinas de mamifero; reactivos y metodos relacionados.
|
WO2001030393A2
(en)
|
1999-10-22 |
2001-05-03 |
Ludwig Institute For Cancer Research |
Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products
|
AU1344102A
(en)
|
2000-10-12 |
2002-04-22 |
Genentech Inc |
Reduced-viscosity concentrated protein formulations
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
US6818216B2
(en)
|
2000-11-28 |
2004-11-16 |
Medimmune, Inc. |
Anti-RSV antibodies
|
EP1801123A3
(en)
|
2000-12-28 |
2007-11-21 |
Altus Pharmaceuticals Inc. |
Crystals of whole antibodies and fragments thereof and methods for making and using them
|
KR20030074693A
(ko)
|
2000-12-28 |
2003-09-19 |
알투스 바이올로직스 인코포레이티드 |
전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
|
WO2002102303A2
(en)
|
2001-05-01 |
2002-12-27 |
Medimmune, Inc. |
Crystals and structure of synagis fab
|
GB0113179D0
(en)
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
AU2002322295C1
(en)
|
2001-06-21 |
2008-12-18 |
Altus Pharmaceuticals Inc. |
Spherical protein particles and methods of making and using them
|
PL222211B1
(pl)
|
2001-06-26 |
2016-07-29 |
Amgen Fremont Inc |
Przeciwciało przeciwko OPGL, kompozycja je zawierająca, jego zastosowanie i sposób jego wytwarzania, sposób wykrywania poziomu OPGL, kompozycja obejmująca polinukleotydy i komórka gosodarza
|
MXPA04000747A
(es)
|
2001-07-25 |
2004-07-08 |
Protein Desing Labs Inc |
Formulacion farmaceutica liofilizada estable de anticuerpos igg.
|
PT1441589E
(pt)
|
2001-11-08 |
2012-08-13 |
Abbott Biotherapeutics Corp |
Formulação farmacêutica líquida estável de anticorpos igg
|
DE10207178A1
(de)
|
2002-02-19 |
2003-09-04 |
Novosom Ag |
Komponenten für die Herstellung amphoterer Liposomen
|
JP4583762B2
(ja)
|
2002-02-27 |
2010-11-17 |
イミュネックス・コーポレーション |
ポリペプチド製剤
|
AU2003226356A1
(en)
|
2002-04-12 |
2003-10-27 |
Ramot At Tel Aviv University Ltd. |
Prevention of brain inflammation as a result of induced autoimmune response
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
FI2206517T3
(fi)
|
2002-07-03 |
2023-10-19 |
Ono Pharmaceutical Co |
Immuunopotentioivia koostumuksia käsittäen anti-PD-L1 -vasta-aineita
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
AU2003265361A1
(en)
|
2002-08-28 |
2004-03-19 |
Pharmacia Corporation |
Stable ph optimized formulation of a modified antibody
|
JP5401001B2
(ja)
|
2002-09-11 |
2014-01-29 |
ジェネンテック, インコーポレイテッド |
免疫関連疾患の治療のための新規組成物と方法
|
AU2003293543A1
(en)
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
JP4511943B2
(ja)
|
2002-12-23 |
2010-07-28 |
ワイス エルエルシー |
Pd−1に対する抗体およびその使用
|
ES2729974T3
(es)
|
2003-01-23 |
2019-11-07 |
Ono Pharmaceutical Co |
Anticuerpo específico de PD-1 y CD3 humanas
|
WO2004071517A2
(en)
|
2003-02-06 |
2004-08-26 |
Schering Corporation |
Uses of il-23 related reagents
|
ZA200506159B
(en)
|
2003-02-10 |
2006-10-25 |
Elan Pharm Inc |
Immunoglobulin formulation and method of preparation thereof
|
AU2004219625B9
(en)
|
2003-03-10 |
2010-12-23 |
Merck Sharp & Dohme Corp. |
Uses of IL-23 agonists and antagonists; related reagents
|
BRPI0403964B8
(pt)
|
2003-04-04 |
2021-05-25 |
Genentech Inc |
formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
|
KR101424624B1
(ko)
|
2003-05-14 |
2014-07-31 |
이뮤노젠 아이엔씨 |
약물 콘쥬게이트 조성물
|
EP1498123A1
(en)
|
2003-07-18 |
2005-01-19 |
Aventis Pharma S.A. |
Emulsifying systems containing azetidine derivatives
|
US20070212346A1
(en)
|
2003-10-09 |
2007-09-13 |
Tomoyuki Igawa |
Highly Concentrated Stabilized Igm Solution
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
PE20090047A1
(es)
|
2003-11-10 |
2009-01-26 |
Schering Corp |
Anticuerpo recombinante humanizado anti-interleuquina 10
|
DE10355904A1
(de)
|
2003-11-29 |
2005-06-30 |
Merck Patent Gmbh |
Feste Formen von anti-EGFR-Antikörpern
|
JPWO2005063291A1
(ja)
|
2003-12-25 |
2007-07-19 |
麒麟麦酒株式会社 |
抗体を含有する安定な水性医薬製剤
|
DK1704166T3
(en)
|
2004-01-07 |
2015-06-01 |
Novartis Vaccines & Diagnostic |
M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
|
RU2390353C2
(ru)
|
2004-02-12 |
2010-05-27 |
Мерк Патент Гмбх |
Высококонцентрированные жидкие композиции анти-egfr антител
|
ATE533502T1
(de)
|
2004-02-17 |
2011-12-15 |
Schering Corp |
Verfahren zur modulation der il-23-aktivität; relevante reagenzien
|
JP4857259B2
(ja)
|
2004-03-24 |
2012-01-18 |
アボット バイオセラピューティクス コーポレイション |
癌細胞増殖を阻害するための抗α5β1抗体の使用
|
EP1755673B1
(en)
|
2004-04-12 |
2014-07-23 |
MedImmune, LLC |
Anti-il-9 antibody formulations and uses thereof
|
WO2005120571A2
(en)
|
2004-06-07 |
2005-12-22 |
Ramot At Tel Aviv University Ltd. |
Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
|
AR049390A1
(es)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
EA016357B1
(ru)
|
2004-07-30 |
2012-04-30 |
Ринат Ньюросайенс Корп. |
Антитела, направленные против бета-амилоидного пептида, и способы их применения
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US20080057070A1
(en)
|
2004-11-04 |
2008-03-06 |
Chiron Corporation |
Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
RU2007124933A
(ru)
|
2005-01-28 |
2009-03-10 |
Вайет (Us) |
Стабилизированные жидкие полипептидные составы
|
DOP2006000029A
(es)
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
CA2600836A1
(en)
|
2005-03-08 |
2006-09-14 |
Pharmacia & Upjohn Company Llc |
Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
|
ES2407468T3
(es)
|
2005-04-18 |
2013-06-12 |
Yeda Research And Development Company Limited |
Formulaciones de anticuerpos anti-hepatitis B (HBV) estabilizadas
|
ATE505489T1
(de)
|
2005-04-22 |
2011-04-15 |
Lilly Co Eli |
Tgf-beta-1-spezifische antikörper
|
LT2439273T
(lt)
|
2005-05-09 |
2019-05-10 |
Ono Pharmaceutical Co., Ltd. |
Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais
|
EP2390267B1
(en)
|
2005-06-07 |
2013-06-05 |
ESBATech - a Novartis Company LLC |
Stable and soluble antibodies inhibiting TNF(alpha)
|
WO2006138315A2
(en)
|
2005-06-15 |
2006-12-28 |
Schering Corporation |
Anti-igf1r antibody formulations
|
JP2009501006A
(ja)
|
2005-06-30 |
2009-01-15 |
セントカー・インコーポレーテツド |
抗il−23抗体、組成物、方法および用途
|
WO2007016562A2
(en)
|
2005-07-29 |
2007-02-08 |
Amgen Inc. |
Formulations that inhibit protein aggregation
|
NZ623901A
(en)
|
2005-08-03 |
2015-10-30 |
Immunogen Inc |
Immunoconjugate formulations
|
PL1937721T3
(pl)
|
2005-08-25 |
2010-12-31 |
Lilly Co Eli |
Przeciwciała anty-IL23
|
EP1931710B1
(en)
|
2005-08-31 |
2017-01-18 |
Merck Sharp & Dohme Corp. |
Engineered anti-il-23 antibodies
|
WO2007033230A2
(en)
|
2005-09-12 |
2007-03-22 |
Novimmune S.A. |
Anti-cd3 antibody formulations
|
KR101363777B1
(ko)
|
2005-09-30 |
2014-02-14 |
메디뮨 리미티드 |
인터루킨―13 항체 조성물
|
WO2007074880A1
(ja)
|
2005-12-28 |
2007-07-05 |
Chugai Seiyaku Kabushiki Kaisha |
抗体含有安定化製剤
|
HUE034269T2
(en)
|
2005-12-29 |
2018-02-28 |
Janssen Biotech Inc |
Human anti-IL-23 antibodies, preparations, methods and applications
|
AU2007212147A1
(en)
|
2006-02-03 |
2007-08-16 |
Medimmune, Llc |
Protein formulations
|
KR20080104160A
(ko)
|
2006-03-28 |
2008-12-01 |
에프. 호프만-라 로슈 아게 |
항-igf-1r 인간 단일클론 항체 제형
|
MEP39508A
(en)
*
|
2006-04-21 |
2011-02-10 |
Novartis Ag |
Antagonist anti-cd40 antibody pharmaceutical compositions
|
EP2021030A2
(en)
|
2006-04-21 |
2009-02-11 |
Amgen, Inc. |
Buffering agents for biopharmaceutical formulations
|
WO2007147019A2
(en)
|
2006-06-13 |
2007-12-21 |
Zymogenetics, Inc. |
Il-17 and il-23 antagonists and methods of using the same
|
EP2081553B1
(en)
|
2006-10-06 |
2020-08-12 |
Amgen Inc. |
Stable antibody formulations
|
EP2094247B1
(en)
|
2006-10-20 |
2022-06-29 |
Amgen Inc. |
Stable polypeptide formulations
|
BRPI0717335A2
(pt)
|
2006-10-27 |
2013-12-10 |
Abbott Biotech Ltd |
Anticorpos anti-htnfalfa cristalinos
|
CA2668947C
(en)
|
2006-12-05 |
2017-02-07 |
Crucell Holland B.V. |
Liquid anti-rabies antibody formulations
|
EP2628752A1
(en)
|
2006-12-14 |
2013-08-21 |
Merck Sharp & Dohme Corp. |
Engineered anti-TSLP antibody
|
CA2790018C
(en)
|
2006-12-21 |
2015-02-03 |
Amgen Inc. |
Formulations
|
CL2008000058A1
(es)
|
2007-01-09 |
2008-05-23 |
Wyeth Corp |
Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden.
|
TWI426918B
(zh)
|
2007-02-12 |
2014-02-21 |
Merck Sharp & Dohme |
Il-23拮抗劑於治療感染之用途
|
US20100055111A1
(en)
|
2007-02-14 |
2010-03-04 |
Med. College Of Georgia Research Institute, Inc. |
Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
|
US20100111966A1
(en)
|
2007-02-23 |
2010-05-06 |
Schering Corporation |
Engineered anti-il-23p19 antibodies
|
CA2678749C
(en)
|
2007-02-23 |
2018-03-13 |
Schering Corporation |
Engineered anti-il-23p19 antibodies
|
NZ598881A
(en)
|
2007-03-29 |
2013-11-29 |
Abbvie Inc |
Crystalline anti-human il-12 antibodies
|
JP5456658B2
(ja)
|
2007-03-30 |
2014-04-02 |
メディミューン,エルエルシー |
抗体製剤
|
US20090208492A1
(en)
|
2007-06-14 |
2009-08-20 |
Elan Pharmaceuticals, Inc. |
Lyophilized Immunoglobulin Formulations and Methods of Preparation
|
CN103977404A
(zh)
|
2007-06-14 |
2014-08-13 |
比奥根艾迪克Ma公司 |
抗体制剂
|
DK2170959T3
(da)
|
2007-06-18 |
2014-01-13 |
Merck Sharp & Dohme |
Antistoffer mod human programmeret dødsreceptor pd-1
|
CA2692165A1
(en)
|
2007-06-25 |
2008-12-31 |
Amgen Inc. |
Compositions of specific binding agents to hepatocyte growth factor
|
UA107557C2
(xx)
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
US20100286038A1
(en)
|
2007-09-21 |
2010-11-11 |
Valentyn Antochshuk |
Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
|
US20090181027A1
(en)
|
2007-09-28 |
2009-07-16 |
Paul Dal Monte |
Anti-IL-12/23p40 Antibodies, Epitopes, Formulations, Compositions, Methods and Uses
|
AR068723A1
(es)
|
2007-10-05 |
2009-12-02 |
Glaxo Group Ltd |
Proteina que se une a antigenos que se une a il-23 humana y sus usos
|
JP5490714B2
(ja)
|
2007-11-28 |
2014-05-14 |
メディミューン,エルエルシー |
タンパク質製剤
|
KR101247418B1
(ko)
|
2007-12-21 |
2013-03-25 |
에프. 호프만-라 로슈 아게 |
항체 제형
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
CA2710775A1
(en)
|
2007-12-28 |
2009-07-09 |
Bioinvent International Ab |
Formulation
|
CN103720587A
(zh)
|
2008-02-07 |
2014-04-16 |
安姆根有限公司 |
稳定化的蛋白组合物
|
BRPI0907718A2
(pt)
|
2008-02-11 |
2017-06-13 |
Curetech Ltd |
método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento
|
WO2009120684A1
(en)
|
2008-03-25 |
2009-10-01 |
Medimmune, Llc |
Antibody formulation
|
SG10201402815VA
(en)
|
2008-04-09 |
2014-09-26 |
Genentech Inc |
Novel compositions and methods for the treatment of immune related diseases
|
CA2726087A1
(en)
|
2008-06-03 |
2009-12-10 |
Tariq Ghayur |
Dual variable domain immunoglobulins and uses thereof
|
JP5945096B2
(ja)
|
2008-07-04 |
2016-07-05 |
小野薬品工業株式会社 |
抗ヒトpd−1抗体の癌に対する治療効果を最適化するための判定マーカーの使用
|
CA2734919C
(en)
|
2008-08-27 |
2016-08-16 |
Schering Corporation |
Lyophilized formulations of engineered anti-il-23p19 antibodies
|
BRPI0917888A2
(pt)
|
2008-09-19 |
2014-02-25 |
Pfizer |
Formulação de anticorpo líquida estável
|
KR101581986B1
(ko)
|
2008-10-29 |
2016-01-04 |
아블린쓰 엔.브이. |
단일 도메인 항원 결합 분자의 제형
|
WO2010062372A2
(en)
|
2008-11-03 |
2010-06-03 |
President And Fellows Of Harvard College |
Methods for modulating nf-kb using gibberellins
|
JP2012509270A
(ja)
|
2008-11-17 |
2012-04-19 |
ジェネンテック, インコーポレイテッド |
生理的条件下での高分子の凝集を低減するための方法及び製剤
|
WO2010069858A1
(en)
|
2008-12-19 |
2010-06-24 |
F. Hoffmann-La Roche Ag |
Pharmaceutical composition
|
EP2403874A1
(en)
|
2009-03-06 |
2012-01-11 |
Genentech, Inc. |
Antibody formulation
|
CN102413839A
(zh)
*
|
2009-03-06 |
2012-04-11 |
医学免疫有限责任公司 |
人源化抗cd19抗体制剂
|
EP2230312A1
(en)
|
2009-03-19 |
2010-09-22 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Probe compound for detecting and isolating enzymes and means and methods using the same
|
RU2560701C2
(ru)
|
2009-05-04 |
2015-08-20 |
Эббви Байотекнолоджи Лтд. |
Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа
|
US9155745B2
(en)
|
2009-06-16 |
2015-10-13 |
Universite De Geneve |
Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs
|
CA2765220A1
(en)
|
2009-07-14 |
2011-01-20 |
Biogen Idec Ma Inc. |
Methods for inhibiting yellow color and peroxide formation in a composition
|
US20120121580A1
(en)
|
2009-07-28 |
2012-05-17 |
Merck Sharp & Dohme Corp. |
Methods for producing high concentration lyophilized pharmaceutical formulations
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
WO2011024862A1
(ja)
|
2009-08-31 |
2011-03-03 |
三洋化成工業株式会社 |
タンパク質水溶液の安定化剤、この安定化剤を含有するタンパク質水溶液及び液体洗剤組成物、並びに、この安定化剤を用いるタンパク質の安定化方法
|
LT3023438T
(lt)
|
2009-09-03 |
2020-05-11 |
Merck Sharp & Dohme Corp. |
Anti-gitr antikūnai
|
EP2473191B1
(en)
|
2009-09-04 |
2017-08-23 |
XOMA Technology Ltd. |
Antibody coformulations
|
CN102753570B
(zh)
|
2009-09-15 |
2016-01-20 |
阿尔泰亚科技公司 |
A蛋白晶体和交联晶体及其使用方法
|
CN102782149B
(zh)
|
2009-11-04 |
2014-11-12 |
默沙东公司 |
经工程改造的抗-tslp抗体
|
KR101989628B1
(ko)
|
2009-12-21 |
2019-06-14 |
제넨테크, 인크. |
항체 제제
|
TWI505838B
(zh)
|
2010-01-20 |
2015-11-01 |
Chugai Pharmaceutical Co Ltd |
Stabilized antibody solution containing
|
US8415507B2
(en)
|
2010-02-03 |
2013-04-09 |
Laurus Labs Private Limited |
Pterostilbene cocrystals
|
US20110256135A1
(en)
|
2010-03-17 |
2011-10-20 |
Wolfgang Fraunhofer |
Anti-nerve growth factor (ngf) antibody compositions
|
EP2566510A1
(en)
|
2010-05-03 |
2013-03-13 |
F. Hoffmann-La Roche AG |
Compositions and methods useful for reducing the viscosity of protein-containing formulations
|
CN103402516B
(zh)
|
2010-06-17 |
2018-01-30 |
富津世生物技术有限公司 |
用作抗病毒药物的化合物、组合物及使用方法
|
EP2399604A1
(en)
|
2010-06-25 |
2011-12-28 |
F. Hoffmann-La Roche AG |
Novel antibody formulation
|
FR2962908A1
(fr)
|
2010-07-20 |
2012-01-27 |
Lfb Biotechnologies |
Formulation d'anticorps anti-cd20
|
WO2012018538A2
(en)
|
2010-07-26 |
2012-02-09 |
Schering Corporation |
Bioassays for determining pd-1 modulation
|
NZ609557A
(en)
|
2010-10-06 |
2014-12-24 |
Regeneron Pharma |
Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
|
CN103517920B
(zh)
|
2011-03-25 |
2018-04-17 |
安进公司 |
抗硬化蛋白(sclerostin)抗体晶体及其制剂
|
CN103429264A
(zh)
*
|
2011-03-31 |
2013-12-04 |
默沙东公司 |
针对人程序性死亡受体pd-1的抗体的稳定制剂和有关的治疗
|
JP2014510152A
(ja)
|
2011-04-07 |
2014-04-24 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
粘度が低減された処方物
|
UY34105A
(es)
|
2011-06-03 |
2012-07-31 |
Lg Life Sciences Ltd |
Formulación líquida estable de etanercept
|
JP6176849B2
(ja)
|
2011-07-19 |
2017-08-09 |
中外製薬株式会社 |
アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
|
AU2012328570B2
(en)
|
2011-10-27 |
2017-08-31 |
Massachusetts Institute Of Technology |
Amino acid derivatives functionalized on the n-terminus capable of forming drug encapsulating microspheres and uses thereof
|
SG11201403792TA
(en)
|
2012-01-23 |
2014-10-30 |
Regeneron Pharma |
Stabilized formulations containing anti-ang2 antibodies
|
EP3412310B1
(en)
|
2012-03-07 |
2022-09-07 |
Cadila Healthcare Limited |
Pharmaceutical formulations of tnf-alpha antibodies
|
WO2013151999A1
(en)
|
2012-04-02 |
2013-10-10 |
President And Fellows Of Harvard College |
Cancer treatment and immune system regulation through fat10 pathway inhibition
|
CN109206516A
(zh)
|
2012-05-03 |
2019-01-15 |
勃林格殷格翰国际有限公司 |
抗IL-23p19抗体
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
EP2866833B1
(en)
|
2012-06-27 |
2019-05-15 |
Merck Sharp & Dohme Corp. |
Crystalline anti-human il-23 antibodies
|
ES2604012T3
(es)
|
2012-07-04 |
2017-03-02 |
F. Hoffmann-La Roche Ag |
Conjugados de antígeno-anticuerpo unidos covalentemente
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
US20140227250A1
(en)
|
2012-08-23 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to tslp
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
WO2014078627A1
(en)
|
2012-11-19 |
2014-05-22 |
Merck Sharp & Dohme Corp. |
Liquid formulations for tnfr:fc fusion proteins
|
WO2014093206A1
(en)
|
2012-12-13 |
2014-06-19 |
Merck Sharp & Dohme Corp. |
Lyophilized spherical pellets of anti-il-23 antibodies
|
US9700633B2
(en)
|
2013-01-28 |
2017-07-11 |
Jenkem Technology Co., Ltd., Tianjin Branch |
Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
|
SG11201506372RA
(en)
|
2013-03-13 |
2015-09-29 |
Seattle Genetics Inc |
Cyclodextrin and antibody-drug conjugate formulations
|
JP6720075B2
(ja)
*
|
2013-05-31 |
2020-07-08 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
癌のための併用療法
|
KR20160030936A
(ko)
|
2013-07-16 |
2016-03-21 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
|
ES2687094T3
(es)
|
2013-07-23 |
2018-10-23 |
Novaliq Gmbh |
Composiciones estabilizadas de anticuerpos
|
TWI649308B
(zh)
|
2013-07-24 |
2019-02-01 |
小野藥品工業股份有限公司 |
喹啉衍生物
|
EP3791862A1
(en)
|
2013-09-11 |
2021-03-17 |
Eagle Biologics, Inc. |
Liquid protein formulations containing viscosity-lowering agents
|
EP3178849B1
(en)
|
2013-09-20 |
2019-03-20 |
Bristol-Myers Squibb Company |
Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
|
EP3057612B1
(en)
|
2013-10-16 |
2020-05-06 |
Merck Sharp & Dohme Corp. |
Method of obtaining thermostable dried vaccine formulations
|
US20170107300A1
(en)
|
2014-03-21 |
2017-04-20 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
|
RU2589691C2
(ru)
|
2014-06-16 |
2016-07-10 |
Общество с ограниченной ответственностью "Промоген-МАТ" |
Стабильная композиция антитела, специфически связывающегося с her2 рецепторами, и способ ее получения
|
US20160074515A1
(en)
|
2014-06-20 |
2016-03-17 |
Reform Biologics, Llc |
Viscosity-reducing excipient compounds for protein formulations
|
AU2015289533B2
(en)
|
2014-07-18 |
2021-04-01 |
Advaxis, Inc. |
Combination of a PD-1 antagonist and a Listeria-based vaccine for treating prostate cancer
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
ES2921875T3
(es)
|
2014-08-11 |
2022-09-01 |
Acerta Pharma Bv |
Combinaciones terapéuticas de un inhibidor BTK, un inhibidor PD-1 y/o un inhibidor PD-L1
|
IL250583B
(en)
|
2014-08-19 |
2022-07-01 |
Merck Sharp & Dohme |
Anti-tigit antibodies
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
AU2015338974B2
(en)
|
2014-10-31 |
2021-08-26 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
WO2016081384A1
(en)
|
2014-11-17 |
2016-05-26 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
WO2016103093A1
(en)
|
2014-12-23 |
2016-06-30 |
Pfizer Inc. |
Stable aqueous antibody formulation for anti tnf alpha antibodies
|
TWI708786B
(zh)
|
2014-12-23 |
2020-11-01 |
美商必治妥美雅史谷比公司 |
針對tigit之抗體
|
EP3247408A4
(en)
|
2015-01-20 |
2018-08-22 |
Immunexcite, Inc. |
Compositions and methods for cancer immunotherapy
|
CN107580500B
(zh)
|
2015-02-19 |
2023-05-30 |
康姆普根有限公司 |
抗pvrig抗体和使用方法
|
AR103726A1
(es)
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
Cristales de anticuerpos monoclonales anti-pd-1 humanos
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
WO2016161410A2
(en)
*
|
2015-04-03 |
2016-10-06 |
Xoma Technology Ltd. |
Treatment of cancer using inhibitors of tgf-beta and pd-1
|
TN2017000440A1
(en)
*
|
2015-04-17 |
2019-04-12 |
Bristol Myers Squibb Co |
Compositions comprising a combination of an anti-pd-1 antibody and another antibody
|
WO2016176504A1
(en)
|
2015-04-28 |
2016-11-03 |
Bristol-Myers Squibb Company |
Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
WO2017009813A1
(en)
|
2015-07-16 |
2017-01-19 |
Laurus Labs Private Limited |
Novel caffeine cocrystals and their polymorphic forms
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
US10766957B2
(en)
|
2015-08-14 |
2020-09-08 |
Merck Sharp & Dohme Corp |
Anti-TIGIT antibodies
|
MX2018002586A
(es)
|
2015-09-01 |
2020-11-24 |
First Wave Bio Inc |
Composiciones para usarse en el tratamiento de afecciones asociadas a una repsuesta inflamatoria anómala.
|
EP3798234A1
(en)
|
2015-09-02 |
2021-03-31 |
Immutep S.A.S. |
Anti-lag-3 agonistic antibodies
|
EP3349792A1
(en)
|
2015-09-14 |
2018-07-25 |
Compass Therapeutics LLC |
Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-
|
CR20220186A
(es)
|
2015-09-25 |
2022-07-07 |
Genentech Inc |
ANTICUERPOS ANTI-TIGIT Y MÉTODOS DE USO (divisional 2018-0225)
|
US20170097333A1
(en)
|
2015-09-28 |
2017-04-06 |
Merck Sharp & Dohme Corp. |
Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents
|
AU2016329960A1
(en)
*
|
2015-09-28 |
2018-04-26 |
Jiangsu Hengrui Medicine Co., Ltd. |
Stable anti-PD-1 antibody pharmaceutical preparation and application thereof in medicine
|
CN108368176B
(zh)
|
2015-10-01 |
2022-06-07 |
波滕扎治疗公司 |
抗tigit抗原结合蛋白及其使用方法
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
CN113599533A
(zh)
|
2015-11-25 |
2021-11-05 |
乐高化学生物科学股份有限公司 |
包含分支接头的抗体-药物缀合物及其相关方法
|
US20190010224A1
(en)
|
2015-12-22 |
2019-01-10 |
Merck Sharp & Dohme Corp. |
Formulations of engineered anti-il-10 antibodies
|
US10221242B2
(en)
|
2016-01-21 |
2019-03-05 |
Pfizer Inc. |
Antibodies specific for epidermal growth factor receptor variant III and their uses
|
AR108516A1
(es)
|
2016-05-18 |
2018-08-29 |
Boehringer Ingelheim Int |
Moléculas de anticuerpo anti-pd1 y anti-lag3 para el tratamiento del cáncer
|
MX2018015592A
(es)
|
2016-06-14 |
2019-04-24 |
Xencor Inc |
Anticuerpos inhibidores de puntos de control biespecificos.
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
AU2017342559B2
(en)
|
2016-10-14 |
2022-03-24 |
Xencor, Inc. |
Bispecific heterodimeric fusion proteins containing IL-15/IL-15Ralpha Fc-fusion proteins and PD-1 antibody fragments
|
US20190374639A1
(en)
|
2016-11-21 |
2019-12-12 |
Polpharma Biologics S.A. |
Aqueous pharmaceutical formulations
|
TWI761453B
(zh)
|
2017-03-01 |
2022-04-21 |
英商梅迪繆思有限公司 |
抗rsv單株抗體配製物
|
CA3054386A1
(en)
|
2017-03-01 |
2018-09-07 |
Medimmune Limited |
Formulations of monoclonal antibodies
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
AU2018263837A1
(en)
|
2017-05-02 |
2019-12-05 |
Merck Sharp & Dohme Llc |
Stable formulations of anti-CTLA4 antibodies alone and in combination with programmed death receptor 1 (PD-1) antibodies and methods of use thereof
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
CA3060581A1
(en)
|
2017-05-02 |
2018-11-08 |
Merck Sharp & Dohme Corp. |
Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
|
CA3074565A1
(en)
|
2017-09-05 |
2019-03-14 |
Merck Sharp & Dohme Corp. |
Compounds for reducing the viscosity of biological formulations
|
JP2022512855A
(ja)
|
2018-11-07 |
2022-02-07 |
メルク・シャープ・アンド・ドーム・コーポレーション |
抗lag3抗体および抗pd-1抗体の共-製剤
|